Skip to main content
Premium Trial:

Request an Annual Quote

Roche Gets CE Mark for Mutation Profiler Software for NGS Cancer Tests

NEW YORK (GenomeWeb) – Roche said today that it has received the CE mark for its Navify Mutation Profiler clinical software, which it launched today.

The software provides annotation, interpretation, and clinical reporting of next-generation sequencing tests for cancer. Along with it, Roche launched Navify Therapy Matcher, an optional clinical decision support app that helps clinicians link clinically actionable mutations to therapy options.

The two products "offer a clinical decision support solution that addresses a major workflow challenge for NGS labs, synthesizing large amounts of medical and scientific data into actionable insights," said Neil Gunn, head of Roche Sequencing Solutions, in a statement.

The Scan

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.